Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Duval, Michel
STAR, NCT04018937: Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation	Active, not recruiting	2	43	Canada, US	Alemtuzumab, Campath, Fludarabine, Fludara, Melphalan, Alkeran, Evomela	Emory University	Sickle Cell Disease	11/26	11/26
BXCL701-201, NCT03910660: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. Initial interim data from trial in combination with BXCL701 for treatment-emergent neuroendocrine prostate cancer Oct 2020 - Oct 2020: Initial interim data from trial in combination with BXCL701 for treatment-emergent neuroendocrine prostate cancer Data from P1b part of P1b/2 trial in combination with BXCL701 for Neuroendocrine prostate cancer Apr 2020 - Apr 2020: Data from P1b part of P1b/2 trial in combination with BXCL701 for Neuroendocrine prostate cancer	Active, not recruiting	1b/2	98	Europe, US	BXCL701 plus Pembrolizumab, BXCL701 plus Pembro, BXCL701 monotherapy, BXCL701	BioXcel Therapeutics Inc	Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma	10/23	12/25